Harriet Wikman-Kocher

Harriet Wikman-Kocher

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2014 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
VLValerie S. LeBleu
Valerie S. LeBleu
JOJoyce T. O’connell
Joyce T. O’connell
KHKarina N. Gonzalez Herrera
Karina N. Gonzalez Herrera
HWHarriet Wikman-Kocher
Harriet Wikman-Kocher
KPKlaus Pantel
Klaus Pantel
RKRaghu Kalluri
Raghu Kalluri
Cancer cells can divert metabolites into anabolic pathways to support their rapid proliferation and to accumulate the cellular building blocks required for tumour growth. However, the specific bioenergetic profile of invasive and metastatic cancer cells is unknown. Here we report that migratory/invasive cancer cells specifically favour mitochondrial respiration and increased ATP production. Invasive cancer cells use the transcription coactivator peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PPARGC1A, also known as PGC-1α) to enhance oxidative phosphorylation, mitochondrial biogenesis and the oxygen consumption rate. Clinical analysis of human invasive breast cancers revealed a strong correlation between PGC-1α expression in invasive cancer cells and the formation of distant metastases. Silencing of PGC-1α in cancer cells suspended their invasive potential and attenuated metastasis without affecting proliferation, primary tumour growth or the epithelial-to-mesenchymal program. Inherent genetics of cancer cells can determine the transcriptome framework associated with invasion and metastasis, and mitochondrial biogenesis and respiration induced by PGC-1α are also essential for functional motility of cancer cells and metastasis.

11 October 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
CECorinna Eichelser
Corinna Eichelser
ISIsabel Stückrath
Isabel Stückrath
VMVolkmar Müller
Volkmar Müller
KMKarin Milde-Langosch
Karin Milde-Langosch
HWHarriet Wikman-Kocher
Harriet Wikman-Kocher
HSHeidi Schwarzenbach
Heidi Schwarzenbach
Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients

19 January 2016 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
IWIsabell Witzel
Isabell Witzel
LOLeticia Oliveira-Ferrer
Leticia Oliveira-Ferrer
KPKlaus Pantel
Klaus Pantel
VMVolkmar Mueller
Volkmar Mueller
HWHarriet Wikman-Kocher
Harriet Wikman-Kocher
Because of improvements in the treatment of patients with metastatic breast cancer, the development of brain metastases (BM) has become a major limitation of life expectancy and quality of life for many breast cancer patients. The improvement of management strategies for BM is thus an important clinical challenge, especially among high-risk patients such as human epidermal growth factor receptor 2-positive and triple-negative patients. However, the formation of BM as a multistep process is thus far poorly understood. To grow in the brain, single tumor cells must pass through the tight blood–brain barrier (BBB). The BBB represents an obstacle for circulating tumor cells entering the brain, but it also plays a protective role against immune cell and toxic agents once metastatic cells have colonized the cerebral compartment. Furthermore, animal studies have shown that, after passing the BBB, the tumor cells not only require close contact with endothelial cells but also interact closely with many different brain residential cells. Thus, in addition to a genetic predisposition of the tumor cells, cellular adaptation processes within the new microenvironment may also determine the ability of a tumor cell to metastasize. In this review, we summarize the biology of breast cancer that has spread into the brain and discuss the implications for current and potential future treatment strategies.

25 August 2008 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
SRSabine Riethdorf
Sabine Riethdorf
HWHarriet Wikman-Kocher
Harriet Wikman-Kocher
KPKlaus Pantel
Klaus Pantel

30 August 2022 in Cell Reports
Verified
Journal Article
Open access
TPThais Pereira-Veiga
Thais Pereira-Veiga
SSSvenja Schneegans
Svenja Schneegans
KPKlaus Pantel
Klaus Pantel
HWHarriet Wikman-Kocher
Harriet Wikman-Kocher
Circulating tumor cells (CTCs) are the seeds of distant metastasis, and the number of CTCs detected in the blood of cancer patients is associated with a worse prognosis. CTCs face critical challenges for their survival in circulation, such as anoikis, shearing forces, and immune surveillance. Thus, understanding the mechanisms and interactions of CTCs within the blood microenvironment is crucial for better understanding of metastatic progression and the development of novel treatment strategies. CTCs interact with different hematopoietic cells, such as platelets, red blood cells, neutrophils, macrophages, natural killer (NK) cells, lymphocytes, endothelial cells, and cancer-associated fibroblasts, which can affect CTC survival in blood. This interaction may take place either via direct cell-cell contact or through secreted molecules. Here, we review interactions of CTCs with blood cells and discuss the potential clinical relevance of these interactions as biomarkers or as targets for anti-metastatic therapies.

20 January 2016 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
GHG.E. Hvichia
G.E. Hvichia
ZPZ. Parveen
Z. Parveen
CWC. Wagner
C. Wagner
MJM. Janning
M. Janning
JQJ. Quidde
J. Quidde
TGT.M. Gorges
T.M. Gorges
Circulating tumor cells (CTCs) were introduced as biomarkers more than 10 years ago, but capture of viable CTCs at high purity from peripheral blood of cancer patients is still a major technical challenge. Here, we report a novel microfluidic platform designed for marker independent capture of CTCs. The Parsortix™ cell separation system provides size and deformability‐based enrichment with automated staining for cell identification, and subsequent recovery (harvesting) of cells from the device. Using the Parsortix™ system, average cell capture inside the device ranged between 42% and 70%. Subsequent harvest of cells from the device ranged between 54% and 69% of cells captured. Most importantly, 99% of the isolated tumor cells were viable after processing in spiking experiments as well as after harvesting from patient samples and still functional for downstream molecular analysis as demonstrated by mRNA characterization and array‐based comparative genomic hybridization. Analyzing clinical blood samples from metastatic (n = 20) and nonmetastatic (n = 6) cancer patients in parallel with CellSearch® system, we found that there was no statistically significant difference between the quantitative behavior of the two systems in this set of twenty six paired separations. In conclusion, the epitope independent Parsortix™ system enables the isolation of viable CTCs at a very high purity. Using this system, viable tumor cells are easily accessible and ready for molecular and functional analysis. The system's ability for enumeration and molecular characterization of EpCAM‐negative CTCs will help to broaden research into the mechanisms of cancer as well as facilitating the use of CTCs as “liquid biopsies.”